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Beta cell dysfunction and insulin resistance are inherently complex with their interrelation
for triggering the pathogenesis of diabetes also somewhat undefined. Both pathogenic
states induce hyperglycemia and therefore increase insulin demand. Beta cell dysfunction
results from inadequate glucose sensing to stimulate insulin secretion therefore elevated
glucose concentrations prevail. Persistently elevated glucose concentrations above the
physiological range result in the manifestation of hyperglycemia. With systemic insulin
resistance, insulin signaling within glucose recipient tissues is defective therefore hyper-
glycemia perseveres. Beta cell dysfunction supersedes insulin resistance in inducing
diabetes. Both pathological states influence each other and presumably synergistically
exacerbate diabetes. Preserving beta cell function and insulin signaling in beta cells and
insulin signaling in the glucose recipient tissues will maintain glucose homeostasis.
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INTRODUCTION
Both beta cell dysfunction and insulin resistance lead to persis-
tent hyperglycemia which characterizes type 2 diabetes. Many
of the susceptibility genes associated with type 2 diabetes by
genome-wide investigations (GWAS) were identified as regula-
tors of cell turnover or regeneration (McCarthy and Hattersley,
2008). Most risk variants for type 2 diabetes in healthy popula-
tions act through impairing insulin secretion (resulting in beta
cell dysfunction) rather than insulin action (resulting in insulin
resistance) which establishes that inherited abnormalities of beta
cell function or mass (or both) are critical precursors in type 2
diabetes (Florez, 2008; McCarthy, 2010; Voight et al., 2010; Petrie
et al., 2011). Recent linkage studies and GWAS have identified>40
genes that increase the risk of type 2 diabetes with the most impor-
tant diabetes susceptibility gene identified as transcription factor
7-like 2 (tcf7l2), which increases diabetes risk 1.7-fold (Ashcroft
and Rorsman, 2012). Potassium voltage-gated channel, KQT-like
subfamily, member 1 (Kcnq1) is a type 2 diabetes susceptibil-
ity gene implicated in reduced beta cell function and decreased
insulin secretion (Bonnefond et al., 2010). Common variants in
several neonatal diabetes mellitus and maturity-onset diabetes of
the young (MODY) [e.g., potassium inwardly rectifying channel,
subfamily J, member 11 (kcnj11), glucokinase (gck), hepatocyte
nuclear factor 4 alpha (hnf1α), and hnf1β] are recognized as type
2 diabetes susceptibility variants 6 and 43 (Bonnefond et al.,
2010). Reduced expression of the transcription factor, prospero
homeobox 1 (Prox1), by cis-regulatory variants altered beta cell
insulin secretion which conferred susceptibility to type 2 diabetes
(Lecompte et al., 2013).
Beta cell dysfunction is the critical determinant for type 2 dia-
betes (Ashcroft and Rorsman, 2012) which is compounded by
insulin resistance. The interplay between beta cell dysfunction and
insulin resistance remains highly complex. The onset of hyper-
glycemia can trigger both beta cell dysfunction and insulin resis-
tance (Figure 1). Beta cell dysfunction is more severe than insulin
resistance (Figure 1). With beta cell dysfunction, insulin secretion
is impaired whereas with insulin resistance, insulin may still be
secreted but insulin insensitivity manifests in target tissues. As beta
cell dysfunction and insulin resistance exacerbate, hyperglycemia
amplifies leading to the progression to type 2 diabetes (Figure 1).
This review focuses on beta cells: physiology and integrity, demise
and dysfunction, compensation, and preservation.
BETA CELL PHYSIOLOGY AND INTEGRITY
Adequate and proper beta cell function requires normal beta cell
integrity which is critical for the appropriate response to perpet-
ual fluctuating metabolic demand for insulin. Genes implicated
in cell-cycle regulation are suggested to influence beta cell mass
during development (Ashcroft and Rorsman, 2012). A decrease in
beta cell mass of≤60% has been reported in type 2 diabetes (Butler
et al., 2003), which parallels the extent of reduction in glucose-
stimulated insulin secretion (GSIS) (Del Guerra et al., 2005) but,
however, considerably lower decrements have been found (Rahier
et al., 2008). Although beta cell mass plays a role in type 2 diabetes,
beta cell function rather than number is more critical in the etiol-
ogy of type 2 diabetes (Ashcroft and Rorsman, 2012). Beta cells are
resilient and will compensate to cope with insulin demand despite
reduced numbers.
Under physiological conditions, the maintenance of blood glu-
cose concentrations within a narrow physiological range relies
on coordinated regulation of insulin secretion through nutri-
ent availability, hormones, and neural inputs (Schrimpe-Rutledge
et al., 2012). Amongst these factors, glucose is by far the most
potent and physiologically important regulator of beta cell func-
tion through coordinated stimulation of insulin gene transcrip-
tion, proinsulin biosynthesis, and insulin secretion from beta
cells (Henquin et al., 2006). The highly coordinated regulation
of gene and protein expression in response to glucose stimulation
is responsible for many established cellular functions such as gly-
colysis and insulin biosynthesis/secretion, but also for unknown
responses (Schrimpe-Rutledge et al., 2012). Glucose is a major reg-
ulator of transcription and translation in beta cells, an effect that
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FIGURE 1 | Hyperglycemia-induced beta cell dysfunction, insulin
resistance, and type 2 diabetes.
is necessary for the long-term maintenance of the highly differ-
entiated state of the cell and the secretory requirements imposed
by prolonged elevations of glucose concentrations (Schuit et al.,
2002). In addition, considering that beta cells are highly metabol-
ically active and that insulin secretion is tightly coupled to glucose
metabolism, the most highly glucose regulated proteins are impli-
cated in glucose metabolism (Schrimpe-Rutledge et al., 2012).
Glucose is therefore a critical determinant of beta cell function –
persistent hyperglycemia may exhaust beta cells whereas hypos-
timulation may prime beta cells for low glycemic states (fasting and
starvation) potentially limiting their response to hyperglycemic
excursions.
BETA CELL DEMISE AND DYSFUNCTION
Beta cell insults include cytokine-induced inflammation, obesity
and insulin resistance, and overconsumption of saturated fat and
free fatty acids (FFA). A progressive decline of beta cell function
leading to beta cell exhaustion precedes beta cell demise (Fer-
rannini, 2010; Talchai et al., 2012). Loss of beta cell mass and
function are central to the development of both type 1 and 2
diabetes (Stoffers, 2004).
CYTOKINES, OXIDATIVE STRESS, ENDOPLASMIC RETICULUM STRESS,
AND INFLAMMATION
Specific proinflammatory cytokines induce an inflammatory
response. Inflammation is associated with obesity and both are
linked to insulin resistance. Proinflammatory cytokines cause beta
cell death via the induction of mitochondrial stress and other
responses (Cnop et al., 2005; Eizirik and Cnop, 2010; Gurgul-
Convey et al., 2011). Cytokines secreted by immune cells that have
infiltrated the pancreas are reported to be crucial mediators of beta
cell destruction (Lin et al., 2012).
Chronic exposure hyperglycemia, leading to oxidative stress
and inflammation, may induce changes in the regulation of
gene expression that converge on impaired insulin secretion and
increased apoptosis (Gilbert and Liu, 2012). Oxidative stress leads
to damage in organelles, particularly the mitochondria and cellular
proteins, lipids, and nucleic acids (Simmons, 2007); it also initi-
ates and contributes to both endoplasmic reticulum (ER) stress
(Kaneto et al., 2005; Hotamisligil, 2010) and autophagy (Lee et al.,
2012), although these mechanisms are not completely defined
(Yuzefovych et al., 2013). ER stress is associated with beta cell
apoptosis in type 2 diabetes (Marchetti et al., 2007).
Reactive oxygen species (ROS) and reactive nitrogen species
(RNS) are formed during both cytokine-mediated proinflamma-
tory beta cell aggression in type 1 diabetes and glucolipotoxicity-
mediated beta cell dysfunction in type 2 diabetes (Evans et al.,
2003; Cnop et al., 2005; Robertson et al., 2007; Lenzen, 2008).
Increased ROS production from mitochondrial overstimulation
and RNS from excess nitric oxide (NO) production in beta cells
leads to the inhibition of the electron transport chain resulting in
reduced energy production, DNA damage, and the formation of
advanced glycation end products (AGEs) (Drews et al., 2010).
The limited glycolytic capacity of beta cells can generate ROS
and the ensuing oxidative stress can uncouple glucose sensing from
insulin secretion (Robertson, 2004). Beta cells are highly depen-
dent on ATP production for GSIS and are vulnerable to excess
ROS because of their inherently low expression of antioxidant
enzymes (Simmons, 2007). The imbalance or reduced availability
of nutrients to beta cells, small repeated increases in ROS pro-
duction, lower ATP synthesis, and inadequate antioxidant balance
may predispose to beta cell dysfunction (Reusens et al., 2011).
OBESITY AND INSULIN RESISTANCE
Obesity is a state of low grade inflammation. Adipose tissue is a
major source of inflammation with the infiltration of macrophages
as the primary source of cytokines in obese individuals (Stienstra
et al., 2007). The beta cells secrete insulin to facilitate glucose
uptake into glucose recipient organs (mainly the muscle, brain,
liver, and adipose tissue). Obesity is a key risk factor for type 2
diabetes as it desensitizes glucose recipient organs to the action of
insulin. Saturated fats are strongly associated with insulin resis-
tance and beta cell dysfunction. High saturated fats in circulation,
derived mainly from diets or even from lipolysis of fat depots, lead
to fatty acids and glucose competing for uptake and metabolism
in tissues. With persistent hyperglycemia, increased saturated FFA
induce a glucolipotoxic state that is detrimental to beta cells by
increasing oxidative stress, subsequently reducing insulin synthe-
sis and secretion thereby compromising both beta cell structure
and function.
The genetic architecture of quantitative indices of beta cell
function and of insulin resistance differ markedly: given the same
individuals, sample sizes, and biochemical measurements, more
signals were described for beta cell function compared to insulin
resistance (Dupuis et al., 2010; Voight et al., 2010). This infers
that beta cell function supersedes insulin resistance as the critical
determinant of type 2 diabetes. Further, as obesity is a critical
determinant of insulin resistance, adiposity may modulate the
genetic determinants of insulin resistance and contribute to the
heterogeneity of type 2 diabetes (Manning et al., 2012). In addi-
tion, the adipokine hormones and proinflammatory cytokines that
are produced by adipose tissue can influence insulin signaling via
diverse mechanisms (Shoelson et al., 2006; Trujillo and Scherer,
2006) and these processes may interact with genetic variants influ-
encing insulin resistance pathways (Manning et al., 2012). Adipos-
ity levels have the potential to perturb the physiological milieu
in which genetic variants in insulin signaling pathways operate
(Manning et al., 2012). Therefore adiposity, and particularly fat in
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the pancreas and major glucose recipient organs, will exacerbate
insulin resistance which consequently impairs beta cell function.
Obesity also increases insulin demand therefore hyperfunction of
beta cells may exhaust beta cells resulting in beta cell dysfunction.
By upregulating insulin secretion (Bergman, 2005) and the
degree to which individuals are capable of achieving this deter-
mines whether or not an individual develops diabetes (Ashcroft
and Rorsman, 2012). This, in turn, is influenced by their genetic
constitution which explains why some obese and insulin resis-
tant individuals do not develop type 2 diabetes; their beta cells
can compensate (Ashcroft and Rorsman, 2012). In those individ-
uals who develop diabetes, beta cell compensation declines due
to hyperglycemia resulting in a persistent progressively increasing
metabolic load that is influenced by factors such as aging and an
increase in the number and severity of diabetogenic risk factors.
SATURATED FAT AND FFA trigger BETA CELL DYSFUNCTION AND
INSULIN RESISTANCE
Higher body mass indices (BMIs) may potentiate the effect of
genetic variants on insulin resistance pathways, an effect that
could be attributed to tissue-specific responses to the obesogenic
environment (Prudente et al., 2009). The effects of FFA on beta
cell function are time dependent. Short-term exposure to FFA
increases GSIS which results in increased insulin secretion fol-
lowing a mixed meal and enables storage of excess calories as fat
(Ashcroft and Rorsman, 2012) which contributes to overweight
and obesity. FFA may account for the compensatory upregulation
of beta cell function in response to insulin resistance (Stefanovski
et al., 2011). Conversely, long-term exposure to FFA suppresses
GSIS and has been suggested to involve impaired glucose metab-
olism, reduced insulin biosynthesis, and beta cell loss (Yaney and
Corkey, 2003; Poitout and Robertson, 2008).
Obesity and high fat feeding mimic the effects of long-term
incubation of islets with FFA on insulin secretion and Ca2+-
channel distribution (Collins et al., 2010) which correlate with
an increased amount of fat within the islets (Hoppa et al., 2009)
and the surrounding exocrine pancreas (Pinnick et al., 2008).
There is also an inverse correlation between the amount of fat
in the human pancreas and GSIS, with glucose tolerance and
insulin secretion improving in parallel with a reduction in pan-
creatic fat (Tushuizen et al., 2007). Intra-pancreatic or intra-islet
fat depots may therefore provide a long-term local source of FFA
that adversely affects beta cell function (Ashcroft and Rorsman,
2012). Obesity coupled to insulin resistance increases the func-
tional demand per beta cell which would increase the burden
and accelerate beta cell dysfunction. The pathogenesis of beta cell
dysfunction may, to a certain extent, mimic hepatic steatosis: intra-
tissue fat depots induce inflammation thereby triggering cellular
demise and dysfunction. Intra-islet, in particular intra-beta cell,
fat could therefore impair GSIS and insulin signaling in islets.
This likely represents a mechanism for beta cell dysfunction and
reduced beta cell compensation that impairs GSIS by non-glucose
sensing by beta cells similar to impaired insulin signaling and con-
sequently glucose uptake in glucose recipient tissues that triggers
insulin resistance.
Islet inflammation (insulitis) in type 2 diabetes is attributed
to nutrient overload leading to metabolic exhaustion in beta cells
(Donath and Shoelson, 2011). This can lead to localized synthesis
of cytokines, resulting in recruitment of immune cells to the site of
production (Donath and Shoelson, 2011) which will trigger beta
cell dysfunction and exacerbate insulin resistance. Nuclear factor
of kappa light polypeptide gene enhancer in B cells (NF-κB) has a
central regulatory role in FFA-induced inflammation and beta cell
death (Choi et al., 2012). The saturated FFA, palmitate, induces
beta cell dysfunction in vivo by activating inflammatory processes
within mouse islets (Eguchi et al., 2012). Palmitate treatment
increased expression of major cytokines implicated in beta cell dys-
function (Choi et al., 2012), viz., interleukin (IL) 6, IL8 (CXCL1),
IP10 [chemokine (C-X-C motif) ligand 10 (CXCL10)], MCP1
(CCL2), and MIP1A (CCL3) (Donath et al., 2010), where they
may influence beta cells in an autocrine manner (Choi et al., 2012).
Insulin sensitivity is impaired by saturated FFA and improved by
polyunsaturated FFA (Siri-Tarino et al., 2010). In rats, saturated
FFA have shown to increase intramuscular palmitic acid accumu-
lation that may lead to insulin resistance (Reynoso et al., 2003). In
humans, a positive association between serum FFA composition
and diabetes was reported (Vessby et al., 1994; Coelho et al., 2011).
BETA CELL COMPENSATION
Upon beta cell demise, beta cell compensation occurs to restore
beta cell physiology. Optimal control of blood glucose concentra-
tions depends on subtle changes in insulin synthesis and secretion
by beta cells and on their capacity for large increases in secre-
tion after meals, requiring large stores of insulin (Tarabra et al.,
2012). It is critical that islets maintain adequate beta cell mass in
response to various fluctuations in demand (Tarabra et al., 2012).
Beta cell mass is enhanced by proliferation (replication of beta
cells), neogenesis (differentiation from non-beta cells), hyperpla-
sia (increased beta cell number) and hypertrophy (increased beta
cell size), and is decreased by beta cell death; through apopto-
sis, necrosis, autophagy, and ferroptosis; hypoplasia (decreased
beta cell number); and hypotrophy (decreased beta cell size). The
expansion and demise of beta cell mass through stimulants and
insults respectively are likely triggered through one or more of
these processes of beta cell replenishment (beta cell expansion)
and death (beta cell demise).
Proliferation refers to an increase in beta cells from beta cell
replication (beta cell self-replenishment) whereas beta cell hyper-
plasia occurs by beta cell replication or beta cell neogenesis from
non-beta cells. Both beta cell replication and neogenesis contribute
to the expansion of beta cell mass and require external stimuli such
as hormones and growth factors (Bouwens and Rooman, 2005).
Beta cells are dynamic and altered in response to fluctuating meta-
bolic demand for insulin. Beta cell hypertrophy and hyperplasia
occur during beta cell compensation to increase beta cell mass in
response to hyperglycemia in diabetogenic states (Cerf et al., 2012).
In several insulin resistant and diabetic rodent models, most islets
were mildly enlarged and displayed hypertrophy and hyperplasia
(Jones et al., 2010). Further, beta cell hypertrophy contributes to
beta cell compensation in high fat diet-induced insulin resistance
and the master beta cell transcription factor, pancreatic duode-
nal homeobox 1 (Pdx1), regulates beta cell size (Sachdeva et al.,
2009), i.e., Pdx1 influences beta cell hyper- or hypotrophy. In con-
trast, beta cell hypotrophy results from beta cell death via various
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processes and insults and contributes to reduced beta cell mass.
In addition, beta cell hypotrophy was found in hyperglycemic
weanling rats exposed to a high fat diet during any single week
of gestation (Cerf et al., 2007). Hyperglycemia may be exacerbated
by the inability of hypotrophic and hypoplastic beta cells to syn-
thesize and secrete sufficient insulin which consequently results in
hypoinsulinemia (Cerf et al., 2007).
In diabetes, reduced beta cell mass occurs through apopto-
sis, necrosis, autophagy, and potentially ferroptosis. In human
type 2 diabetes, both increased apoptosis and reduced replica-
tion may contribute to beta cell loss and reduced beta cell mass
(Karaca et al., 2009). Beta cell hyperplasia and hyperinsuline-
mia compensate for progressively increasing insulin resistance
to maintain normoglycemia; with time apoptosis exceeds the
rate of replication and beta cell mass declines (Kiraly et al.,
2008). The cytokine, IL1, induces beta cell necrosis suggest-
ing that macrophage-derived cytokines participate in the initial
pathogenesis of diabetes by inducing beta cell death by a mecha-
nism that promotes necrosis and islet inflammation (Steer et al.,
2006). Autophagy, a catabolic process that involves the degrada-
tion of cellular components through the lysosomal machinery, is
important for maintaining normal islet homeostasis and compen-
satory beta cell hyperplasia in response to high fat dietary intake
(Ebato et al., 2008). In type 2 diabetic patients, increased beta
cell death was associated with altered autophagy suggesting that
autophagy can be induced by metabolic perturbations (Marchetti
and Masini, 2009). The cell death process of ferroptosis is morpho-
logically, biochemically, and genetically distinct from apoptosis,
various forms of necrosis and autophagy, and is characterized by
iron-dependent accumulation of lethal lipid ROS (Dixon et al.,
2012). The role of ferroptosis in beta cell demise still requires
elucidation.
Beta cells initially compensate for the insulin resistance associ-
ated with obesity by increasing insulin secretion (Kasuga, 2006).
When beta cell loss reaches the point of causing hyperglycemia,
the beta cell replication rate is presumably maximally stimu-
lated; therefore a further elevation in glucose concentrations will
not increase replication (Porat et al., 2011). Glucose homeostasis
maintains normoglycemia by adapting the mass and function of
beta cells that counter insulin resistance, reduced beta cell mass,
and excess nutrition (Liu et al., 2001).
GLUCOSE POTENTIATES BETA CELL PROLIFERATION
The physiology of beta cells and insulin sensitive tissues are associ-
ated and mediated by metabolites, notably glucose. The beta cells
compensate (adapt) in response to fluctuations in the demand
for insulin. In states of increased insulin demand such as hyper-
glycemia, beta cells compensate to restore glucose homeostasis
(maintain normoglycemia) via beta cell hypertrophy, and hyper-
plasia (to collectively increase beta cell mass) (Cerf, 2010) also
increasing insulin biosynthesis (Brissova et al., 2005). Glucose
increases the rate of beta cell proliferation in vitro (Kwon et al.,
2004) and during short periods of glucose infusion in rodents
(Bonner-Weir et al., 1989; Paris et al., 2003; Alonso et al., 2007)
with glucose identified as the key systemic factor controlling beta
cell replication (Porat et al., 2011). All beta cells appear to equally
contribute to growth and maintenance (Brennand et al., 2007).
BETA CELL TRAJECTORIES
Beta cell mass is dynamic and can respond to environmental cues
such as glucose and insulin (Paris et al., 2003). Beta cell number
increases markedly in the first year of rodent life (Montanya et al.,
2000; Dor et al., 2004), up to 1.5-fold during pregnancy (Van Ass-
che et al., 1978; Scaglia et al., 1995) and up to 10-fold in insulin
resistant states (Kulkarni et al., 2004).
When not constrained by persistent autoimmune attack or the
toxicity of persistent hyperglycemia (glucotoxicity) (Ryu et al.,
2001), beta cells inherently have the capacity to regenerate (Bren-
nand et al., 2007). While the mechanism regulating beta cell
expansion remains unclear, all beta cells are capable of replica-
tion (Brennand et al., 2007). Pluripotent stem cells also serve as
sources of new beta cells. This however requires their defined ter-
minal differentiation into functional beta cells which presents a
major challenge.
In rodents, beta cell replication rates in young adult mice
(12 week old) are highly variable from 2% (Finegood et al., 1995)
to 15% per day (Teta et al., 2005). It was assumed that if 5% of beta
cells replicate per day, and that all beta cells are equivalent, beta
cells should divide approximately every 20 days (Brennand et al.,
2007). However, using the range of 2–15% beta cell replication per
day, and factoring in the median of a 8.5% replication rate, it is
possible that beta cells can divide every 12 days, in physiological
states, i.e., in the absence of any persistent hyperglycemic excur-
sions. Altered metabolic states requiring increased insulin demand
will alter beta cell replication rates.
Beta cell replication varies in humans and rodents. Human
beta cells, unlike young rodent beta cells, are long-lived with little
adaptive change during adulthood and are largely established by
20 years (Cnop et al., 2010). In humans, an age-related decrease of
replicating cells reflects decreased adaptability (Reers et al., 2009).
In young rodents (<1 year), the half-life of beta cells is estimated
at 30–60 days (Finegood et al., 1995). In human adult beta cells,
replication is estimated at 10-fold less than in adult mice (Butler
et al., 2003, 2007) with the most replication in<5 year old children
(Meier et al., 2008).
BETA CELL PROLIFERATION: MECHANISMS
During neonatal life, the endocrine pancreas undergoes substan-
tial remodeling, which involves significant apoptosis, replication,
and neogenesis of islet cells (Scaglia et al., 1997; Petrik et al., 1998;
Bonner-Weir et al., 2010). Islet mass grows into adulthood to
match increased hormonal demand (Zhang et al., 2012). In con-
trast, there is little change in islet mass in adults except in response
to physiological and/or pathological changes such as pregnancy
and obesity (Parsons et al., 1992; Weir et al., 2001), while adaptive
islet cell proliferation is severely restricted in aged mice (Rankin
and Kushner, 2009).
By GSIS, beta cells tightly regulate systemic glycemia within
a narrow range. Insufficient functional beta cell mass is the
causal factor of type 1 and a major contributor to type 2 dia-
betes, emphasizing the importance of understanding beta cell
dynamics (Butler et al., 2003; Muoio and Newgard, 2008). In
healthy adult mice, and in mice recovering from a diabetogenic
injury, new beta cells are derived mainly by replication of pre-
existing beta cells (Dor et al., 2004; Georgia and Bhushan, 2004;
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Brennand et al., 2007; Nir et al., 2007; Teta et al., 2007; Meier et al.,
2008).
Signals controlling beta cell number may therefore act by mod-
ulating the survival and/or proliferation of differentiated beta cells
(Porat et al., 2011). Food intake or glucose infusion increases
beta cell replication in mice (Chick and Like, 1971; Chick, 1973;
Bonner-Weir et al., 1989; Alonso et al., 2007) and insulin resistance
results in a compensatory increase in beta cell mass (Kulkarni et al.,
2004). There is evidence that systemic factors control beta cell
proliferation, including the observation of beta cell hyperplasia in
mice lacking insulin receptors in the liver (Michael et al., 2000;
Kulkarni et al., 2004; Okada et al., 2007; Imai et al., 2008), and the
demonstration that systemic factors in insulin resistant animals
induce beta cell proliferation in islet grafts (Flier et al., 2001).
Uncontrolled beta cell proliferation will increase beta cell num-
bers and enhance the functional capacity. However, hypoglycemia
could be a consequence of increased, uncontrolled beta cell pro-
liferation due to an excess of beta cells, and the resultant over
secretion of insulin. Further, increased beta cell numbers will occur
at the expense of other islet cell types that secrete hormones antag-
onistic to insulin to also facilitate glucose homeostasis. Disrupting
the islet cell population will limit the ability for maintaining glu-
cose homeostasis. Apoptosis may also be potentiated to regulate
uncontrolled proliferation. The balance between sustaining pro-
liferation and evading apoptosis is critical for the initial beta cell
compensatory response to normalize glycemia. This delicate shift
to either physiological process has to adapt to metabolic demand. If
this balance is disrupted to favor either process it would exacerbate
the diabetogenic state.
Glucose can increase the rate of beta cell proliferation in vitro
(Kwon et al., 2004) and during short periods of glucose infusion
in vivo (rodents) (Bonner-Weir et al., 1989; Paris et al., 2003;
Alonso et al., 2007). Insulin, FFA, and incretin hormones have
also been proposed as beta cell proliferative agents, particularly
in insulin resistant states where circulating glucose concentrations
are not measurably elevated but several other beta cell mitogens
are yet to be identified (Porat et al., 2011).
A recent study identified a simple mechanism for homeostasis
of beta cell proliferation and mass where beta cells adjust their
proliferation rate according to the rate of glycolysis; this provides
a system for sensitive measurement of organismal demand for beta
cells, while normoglycemia is maintained (Porat et al., 2011). The
same homeostatic mechanism appears to be responsible for the
control of beta cell number during healthy adult life and during
regeneration following injury (Porat et al., 2011). Physiologically,
this model explains how beta cell number can be finely adjusted
according to the organism’s needs without deviating from the
normoglycemic range (Porat et al., 2011).
The capacity of beta cells to proliferate in response to insulin
resistance is critical for glucose homeostasis and for preventing the
progression of type 2 diabetes (Blandino-Rosano et al., 2012). Pro-
liferation of mature beta cells is one of the components responsible
for maintenance of beta cell mass in adult life (Dor et al., 2004).
A highly perfused subpopulation of islets demonstrated a higher
rate of beta cell proliferation (Lau et al., 2012). Islet endothelial
paracrine factors can increase beta cell proliferation (Lau et al.,
2012) and the transcription factor, Islet 1, has been identified as
crucial for sustained beta cell proliferation and the prevention of
apoptosis in postnatal beta cells (Du et al., 2009). Tcf7l2 promotes
beta cell proliferation, protects against apoptosis, and improves
insulin secretion (Loder et al., 2008; Shu et al., 2008, 2009).
Beta cell proliferation progressively reduces with age. Adap-
tive beta cell proliferation is severely restricted with advanced age
(Rankin and Kushner, 2009). In mice, beta cell regeneration, which
occurs mainly by self-renewal, is severely and abruptly restricted by
middle age (Rankin and Kushner, 2009). The regenerative capac-
ity of adult beta cells becomes limited by early middle age (1 year,
about 40% of the life span in mice) (Harrison and Archer, 1987).
Beta cell replication may become fully restricted when adult insulin
requirements are established in middle age (Rankin and Kush-
ner, 2009). In human islets from donors aged 17–74 years, there
was an age-related decreased expression of Pdx1 indicating both
a decreased capacity with age for cellular proliferation (decreased
plasticity) and reduced insulin formation and secretion (Maedler
et al., 2006). A significantly higher incidence of beta cell neogenesis
was observed in the premature and developing human pancreas
(Gregg et al., 2012). Postnatally, human beta cell neogenesis was
observed at a negligible rate of≤0.5% in normal human pancreata
with several rare instances of beta cell neogenesis observed at 1,
15, and 39 years (Gregg et al., 2012).
BETA CELL PRESERVATION
DETERMINANTS OF BETA CELL PRESERVATION
Several recently identified factors regulate beta cells. These factors
are involved in beta cell maintenance (mass, compensation, and
function) and ultimately contribute to beta cell preservation. Beta
cell preservation refers to the maintenance of both beta cell struc-
ture (integrity or architecture including beta cell mass, number,
and size) and function (beta cell physiology).
Serum response factor (SRF), an essential regulator of myo-
genic and neurogenic genes, is highly enriched in beta cells and the
insulin gene is a target of SRF (Sarkar et al., 2011). Insulin gene
expression is glucose responsive; SRF is a glucose concentration
sensitive regulator of insulin gene expression and may therefore
play an important role in glucose homeostasis (Sarkar et al., 2011).
Alpha motif domain containing 4b/harmonin-interacting,
ankyrin repeat-containing protein (Anks4b/Harp) is a target of
HNF4α in beta cells (Sato et al., 2012). Anks4b interacts with glu-
cose regulated protein 78 (GRP78), a major chaperone protein
that protects cells from ER stress in vitro and in vivo (Sato et al.,
2012). HNF4α plays an important role in the regulation of ER
stress and apoptosis in beta cells (Sato et al., 2012). HNF4α and
HNF1α regulate common target genes through interdependent
regulatory mechanisms (Boj et al., 2010). Although the mecha-
nism of the functional interaction between HNF4α and HNF1α is
still unclear, Anks4b gene expression represents another example
of such interdependent regulation (Sato et al., 2012). Anks4b is a
target of HNF4α and uncovers a new role for this transcription
factor in regulating beta cell susceptibility to ER stress (Sato et al.,
2012).
Recently it was shown that uncoupling protein 2 (UCP2) does
not contribute to mitochondrial uncoupling in beta cells in intact
islets (Robson-Doucette et al., 2011). However, there is grow-
ing evidence that implicates mitochondrial dysfunction in the
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pathophysiology of beta cell secretory failure (Mulder and Ling,
2009). Beta cell mitochondria serve as the fuel integrators of beta
cells and generate signals for insulin secretion, the principal being
ATP (Wikstrom et al., 2012). Therefore mitochondrial function
predicts beta cell function as ATP is a key trigger for GSIS. The
respiratory profile of human islets prior to transplantation into
animal models may predict the transplantation outcome (Sweet
et al., 2005, 2008; Papas et al., 2007); i.e., islets with high lev-
els of oxygen consumption were more likely to reverse diabetes
(Wikstrom et al., 2012).
The survival of beta cells in type 2 diabetes is particularly
important as the disease is characterized by a progressive loss of
beta cell numbers due to glucolipotoxicity (Shimabukuro et al.,
1998; El-Assaad et al., 2003) and other insults. MIN6 cells express
constitutively active peroxisome proliferator-activated receptor
(PPARγ) in the presence of high glucose (Rao et al., 2012). More
interestingly however, the reversal of the effect by glucose and
adiponectin to induce insulin release, provides a novel pathway by
which adiponectin accentuates insulin secretion in MIN6 cells and
increases insulin content (Rao et al., 2012).
Hepatocyte growth factor (HGF), the growth inhibitory peptide
or glucose-dependent insulinotropic polypeptide (GIP), the tran-
scription factor paired box gene (Pax4), and the orphan nuclear
liver receptor homolog 1 (LRH1) are factors that exert several ben-
eficial actions on beta cells simultaneously such as conferring beta
cell protection and enhancing proliferation (Mellado-Gil et al.,
2012). In addition, some of these factors have been shown to
improve beta cell function under pathophysiological conditions
(Mellado-Gil et al., 2012). HGF and Pax4 both inhibit the NF-
κB pathway leading to enhanced beta cell survival (Mellado-Gil
et al., 2012). Similarly, GIP and Pax4 enhance expression of the
anti-apoptotic gene bcl2 (Mellado-Gil et al., 2012). HGF and Pax4
also promote trans-differentiation of pancreatic ductal endothelial
cells and alpha cells into beta cells (Mellado-Gil et al., 2012). This
could be extremely beneficial as an alternative method to replenish
functional beta cell mass due to the limited replication capacity of
beta cells (Mellado-Gil et al., 2012). It is also interesting that alpha
cells appear less susceptible to autoimmune attack with an appar-
ent increase in the number of alpha cells in type 2 diabetic patients
(Mellado-Gil et al., 2012). In this context, a combined HGF/c-met,
Pax4, and GIP therapy could be optimal: beta cell protection with
increased proliferation with the generation of new beta cells from
alpha cells (Mellado-Gil et al., 2012).
The preservation of beta cell mass is crucial for islets to maintain
normal glucose concentrations in the face of increasing glycemia
and decreasing insulin sensitivity (Rao et al., 2012). The func-
tional significance of activating PPARγ using thiazolidinedione
(TZD) therapy in type 2 diabetes is to prevent beta cell apop-
tosis as these compounds enhance beta cell survival in diabetic
patients (Ovalle and Bell, 2002; Pelzer et al., 2005). The PPARγ
agonist rosiglitazone prevents beta cell death in db/db mice and
Zucker diabetic fatty (ZDF) rats (Finegood et al., 2001). However,
the critical determinant is whether these preserved beta cells are
fully functional, have compromised function or are redundant.
Preserving beta cells that are not fully functional, i.e., respond
properly and promptly to insulin demands, will compound beta
cell dysfunction and insulin resistance. These cells will occupy the
space of fully functional beta cells thereby compromising collective
insulin synthesis and secretion.
Because replenishing lost beta cells provides a potential cure for
diabetes, identifying molecules capable of inducing endocrine cell
differentiation in animal models and elucidating their mechanism
of action are particularly valuable for diabetes research (Wang
et al., 2008). The transcription factors, myelin transcription factor
(Myt1) and neurogenin (Ngn3), form a feed-forward expression
loop to promote the differentiation of most if not all endocrine
cells (Wang et al., 2008) and therefore present a starting point for
beta cell replenishment.
Some physiological processes also prime beta cells for survival
such as dedifferentiation and autophagy. To avoid demise, beta
cells dedifferentiate, and at a later stage, resume their beta cell
identity and function. Beta cell dedifferentiation is the regression
to an endocrine progenitor-like stage rather than a degenerative
stage (Talchai et al., 2012). By adopting the dedifferentiated fate,
beta cells enhance their survival (Talchai et al., 2012). There is
ample time for transition between functional depletion of insulin
in beta cells and their demise that may allow the salvaging of ded-
ifferentiated beta cells; this presents a novel approach for treating
beta cell dysfunction in diabetes (Talchai et al., 2012).
Autophagy is a pathway for cells to degrade organelles and is
an adapted mechanism for cells to reduce ROS (Scherz-Shouval
and Elazar, 2011) and eliminate ER stress (Ding et al., 2007).
This catabolic process involves the degradation of cellular com-
ponents through the lysosomal machinery and is important for
maintaining normal islet homeostasis and compensatory beta cell
hyperplasia (Ebato et al., 2008). Autophagy plays a key role in the
protection of beta cells from apoptosis, stabilizing beta cell struc-
ture, and maintaining beta cell function (Hur et al., 2010; Las and
Shirihai, 2010). However, in human type 2 diabetes, autophagy
can also contribute to loss of beta cell mass (Masini et al., 2009).
Thus, whether autophagy plays a protective role or harms beta cells
requires further investigation (Wu et al., 2013).
NOVEL TREATMENTS
Treatments for beta cell dysfunction should strive to ameliorate
beta cell structure and/or function, stimulate beta cell prolifera-
tion to enhance beta cell mass and thereby allow compensation to
restore and/or maintain beta cell function. This ultimately main-
tains glucose homeostasis. A recent study emphasized the potential
importance of analyzing molecular pathways to identify potential
therapeutic targets (Koulmanda et al., 2012). Therapeutic strate-
gies aimed at repopulating insulin-producing cells show great
potential for restoring glycemia in diabetes (Feng et al., 2012).
Factors should not be studied in isolation but rather collectively
to mimic physiology.
c-Kit is important in the development and function of islets,
especially in support of beta cell proliferation, maturation, and
survival (Oberg et al., 1994; Oberg-Welsh and Welsh, 1996; LeBras
et al., 1998; Welsh et al., 2000; Rachdi et al., 2001; Yashpal et al.,
2004; Li et al., 2007). c-Kit overexpression in beta cells con-
fers improved glucose metabolism by enhancing insulin secretion
and increases beta cell mass and proliferation, probably through
the activation of the phosphatidylinositol-3-kinase (PI3K)-Akt
signaling pathway (Feng et al., 2012).
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Mimitin, a small 20 kDa mitochondrial protein and direct tar-
get of c-myc, is involved in cell proliferation (Tsuneoka et al., 2005)
and can act as a modulator of GSIS and prevent its inhibition by
proinflammatory cytokines (Hanzelka et al., 2012).
Adiponectin is capable of increasing MIN6 cell proliferation
(Rao et al., 2012). Adiponectin increased MIN6 cell number in
25 mM glucose but had no effect on MIN6 cell proliferation in
3 mM glucose (Rao et al., 2012). This demonstrated that hyper-
glycemia was required for increasing proliferation. Adiponectin
also has positive effects on MIN6 cell proliferation via pathways
unrelated to PPARγ activation (Rao et al., 2012).
Exenatide, a glucagon-like peptide-1 receptor (GLP-1R) ago-
nist, enhances beta cell function and survival during culture condi-
tions used in clinical islet transplantation which presents a feasible
approach to preserve beta cells during pre-transplant islet culture
(Park et al., 2013).
Epoxyoukalide, a marine product, protected against basal and
cytokine-induced apoptosis, maintained beta cell function, and
induced beta cell proliferation mediated by extracellular signal-
regulated kinases (ERK1/2) activation and targets, cyclin D2, and
cyclin R (Lopez-Acosta et al., 2013).
Insulin secretion in the presence of resveratrol is increased in
various pancreatic beta cell cultures (Chen et al., 2007). Pheno-
lic compounds potentially positively preserve beta cells and their
function (Lin et al., 2012). Quercetin and naringenin possibly
protect beta cells from cytokine-induced toxicity by enhancing
cell survival through the PI3K pathway, independent of p-p38
mitogen-activated protein kinases (MAPK), or inducible NO syn-
thase (iNOS) as demonstrated in INS-1 cells (Lin et al., 2012).
In addition, quercetin and naringenin induce pAkt activation and
could further participate in beta cell protection from cytokine-
induced cell apoptosis, possibly by a NO-independent mechanism
and could be potent agents to benefit beta cell mass preservation
(Lin et al., 2012).
HEALTHY DIET AND REGULAR EXERCISE
A healthy normocaloric diet that is well balanced, limited in satu-
rated fat content, and meets the recommended daily allowances
of key nutrients protects beta cells and enhances longevity in
healthy individuals. Reduced energy intake combined with exer-
cise improves insulin sensitivity (Weickert, 2012). Additional
dietary measures that reduce insulin resistance include ingest-
ing a Mediterranean dietary pattern that avoids excess dietary
fat intake; substituting saturated fatty acids and trans fatty acids
with monounsaturated fatty acids and polyunsaturated fatty acids,
emphasizing cereal fiber content in the diet and when on a
high protein diet, maintaining high levels of exercise (Weick-
ert, 2012). Patients with poorly controlled type 2 diabetes who
were placed on a hypocaloric diet for up to 12 weeks experi-
enced a marked and rapid decrease in liver fat content (85%),
associated specifically with normalization in hepatic insulin sensi-
tivity and reductions in fasting hyperglycemia and hepatic glu-
cose production without changes in intramyocellular lipid or
insulin-mediated whole body glucose disposal (Petersen et al.,
2005).
Regular exercise, although it may not necessarily reduce weight,
enhances insulin sensitivity. Importantly, exercise concomitant
with weight loss improves beta cell function (Dela et al., 2004;
Solomon et al., 2010). Exercise maintained or enhanced beta cell
function in older obese individuals, with improved beta cell func-
tion correlating with reduced glucose concentrations (Malin and
Kirwan, 2012). In the ZDF rat, voluntary running prevented the
development of diabetes despite continuing hyperphagia, obesity,
and hyperlipidemia (Delghingaro-Augusto et al., 2012). Compen-
satory insulin secretion was preserved and hyperglycemia pre-
vented by exercise was characterized by enhanced insulin secretion
per islet and the prevention of severe depletion of islet insulin
stores (Delghingaro-Augusto et al., 2012). Frequent exercise and
adopting a healthy diet is a strategy to improve diabetic outcomes,
particularly in pre-diabetic states such as obesity and/or insulin
resistance and beta cell dysfunction.
BETA CELL PROLIFERATION AND COMPENSATION
COUNTERS BETA CELL DEMISE AND DYSFUNCTION BUT
PROMOTES BETA CELL PRESERVATION
Cytokine-mediated oxidative stress and inflammation, inherent in
obesity and insulin resistance, induces beta cell death therefore
the beta cell population declines contributing to the manifes-
tation of beta cell dysfunction (Figure 2). Similarly peripheral
FFA-induced inflammation, as in obesity and insulin resistance,
leads to beta cell destruction and dysfunction (Figure 2). Further,
within the pancreas, saturated FFA induce islet inflammation and
increase cytokine expression in beta cells thereby inducing beta
cell dysfunction.
Metabolites, hormones, and transcription factors stimulate
beta cell proliferation to sustain beta cell compensation (Figure 2).
Beta cell compensation is a critical intervention process: it both
inhibits beta cell demise and dysfunction; and protects beta cell
structure and function (Figure 2).
Proliferative agents, novel compounds, and healthy lifestyles
help to preserve beta cells by maintaining beta cell integrity
and function (Figure 2). Therefore with an adequate (and func-
tional) beta cell population, beta cell physiology is maintained.
Apart from feeding beta cell compensation, beta cell proliferation
also restores beta cell population (when replenishment> death)
thereby contributing to beta cell maintenance.
PERSPECTIVES ON BETA CELL DYSFUNCTION AND INSULIN
RESISTANCE
Beta cell dysfunction signals an advanced state of diabetes as
insufficient insulin is secreted to meet demand. Insulin resistance
precedes the pathogenesis for several modern diseases (Samuel and
Shulman, 2012). Thus understanding the pathogenesis of insulin
resistance has become increasingly important to guide the devel-
opment of future therapies and inform health and economic policy
(Samuel and Shulman, 2012).
The relationship between insulin resistance and beta cell dys-
function is dynamic and largely dependent on the metabolic
state that is primarily determined by glycemic status and con-
sequently insulinemic status. Both a high fat diet and obesity
trigger insulin resistance independently, with a high fat diet con-
tributing to overweight and obesity (Figure 3). In the etiology
of beta cell dysfunction, firstly, beta cell physiology is maintained
in healthy individuals (Figure 3). However, glucolipotoxicity and
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FIGURE 2 | Beta cell proliferation and compensation counters beta cell demise and dysfunction but promotes beta cell survival. Factors are encircled;
proliferating factors are in bold.
FIGURE 3 | Beta cell dysfunction and insulin resistance dynamics.
proinflammatory cytokines induce oxidative stress leading to beta
cell demise, although other stressors exist (Figure 3). Beta cell
compensation occurs when beta cell integrity is diminished. If beta
cell compensation is successful, beta cell physiology is maintained
(Figure 3). However if beta cell compensation is exhausted, beta
cell dysfunction ensues (Figure 3). Insulin resistance impairs
beta cell physiology and compensation thereby inducing beta cell
demise and dysfunction. Beta cell replenishment and preserva-
tion, through novel agents, healthy lifestyles of balanced diets and
regular exercise, maintains beta cell physiology, and compensa-
tion (when necessary) therefore protecting against beta cell demise
and dysfunction (Figure 3). The main intervention strategy is to
maintain sufficient beta cell compensation to restore and maintain
beta cell physiology to avoid beta cell dysfunction and the subse-
quent progression to diabetes. This is achieved by maintaining
adequate beta cell preservation, i.e., by preserving beta cell struc-
ture and function, and replenishment by lifestyle and, if necessary,
therapeutic interventions.
Beta cell physiology should be preserved throughout life but is
adversely impacted with aging and altered metabolic states such
as obesity that requires a sustained increase in insulin. Insulin
resistance promotes beta cell demise and inhibits beta cell com-
pensation which thereby promotes beta cell dysfunction. Replen-
ishing or preserving beta cells maintains beta cell physiology
and allows for beta cell compensation which combats beta cell
demise and beta cell dysfunction. The preservation of beta cells by
replenishment to mitigate against insults and maintain beta cell
physiology will improve the metabolic outcomes associated with
diabetes.
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